Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

Share this content:
Rubraca has been shown to lead to complete or partial reduction of the tumor in 54% of women over 9.2 months, according to a press statement.
Rubraca has been shown to lead to complete or partial reduction of the tumor in 54% of women over 9.2 months, according to a press statement.

Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with BRCA-positive ovarian cancer that have already received 2 or more chemotherapies.1 

It is estimated that over 22,000 women were diagnosed with ovarian cancer in 2016 and about 15% to 20% of these will have the BRCA gene mutation.1

Rubraca, a PARP inhibitor, was developed by researchers at Newcastle University and has been shown to lead to complete or partial reduction of the tumor in 54% of women over an average of 9.2 months, according to a press statement. PARP inhibitors target the tumors cell's DNA repair mechanisms leading to cell death without affecting healthy cells.2

Yvette Drew, MBBS, MRCP, PhD, a senior lecturer at Newcastle University and honorary consultant in medical oncology at Newcastle upon Tyne Hospitals NHS Foundation Trust who helped lead the clinical development of Rubraca said in a press release, “Rubraca is a well-tolerated oral drug, allowing women to have a better quality of life for longer without debilitating side effects that are often seen with chemotherapy. The approval of this medication is a great achievement for the Newcastle University team and is an example of what can be achieved when scientists and oncologists work together to target a specific type of cancer at the molecular level.”2

References

1. FDA grants accelerated approval to new treatment for advanced ovarian cancer [news release]. Silver Spring, MD: FDA Website; December 19, 2016. www.fda.gov/newsevents/newsroom/pressannouncements/ucm533873.htm. Accessed April 23, 2017.

1. Ovarian cancer patients get access to life-extending drug [news release]. United Kingdom: Newcastle University Press Office; April 7, 2017. www.ncl.ac.uk/press/news/2017/04/rubracafadapproval/. Accessed April 23, 2017.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs